Biosimilar

In this episode, host Shikha Jain, MD, speaks with Jorge García, PharmD, about the economic benefits of biosimilars, the unique perspective pharmacists bring to cancer care costs and more.

The FDA has approved a citrate-free, high-concentration formulation of the adalimumab biosimilar Hyrimoz, according to a press release from the manufacturer.

Mandatory switching policies for biosimilars are “much more” effective in increasing adoption than focusing on new start strategies, according to a study of Canadian health spending data published in Arthritis Care & Research.

A post hoc analysis of phase 3 trial data showed no association of immunogenicity with efficacy or safety for both ranibizumab and the biosimilar SB11 in patients with neovascular age-related macular degeneration.

Most gastroenterologists reported higher familiarity with adalimumab biosimilars and reported greater comfort levels in prescribing biosimilars than dermatologists or rheumatologists, according to a recent survey.

Although most rheumatologists report they are comfortable with the idea of prescribing biosimilars, only approximately 18% think the economic benefits warrant switching their patients to one, according to a Cardinal Health survey.

PB006, the first biosimilar for natalizumab, showed comparable safety, efficacy and immunogenicity to the reference monoclonal antibody therapy in patients with relapsing-remitting MS, researchers wrote in JAMA Neurology.

DENVER — Proactively educating patients on biosimilar efficacy and cost-savings associated with their use can help reduce anxiety and bias if/when their insurance opts to switch, according to a presenter at the Crohn’s and Colitis Congress.

The past year has seen quite a few new developments in inflammatory bowel disease therapy.

In 2021, Humira — the blockbuster biologic that has for years been the highest grossing drug in the world — accomplished something that no drug had previously achieved when its global revenues topped $20 billion.